Introduction
The transcriptional activator (Tat) protein of the human immunodeficiency virus type 1 (HIV-1) induces elongation of transcription of HIV-1 viral genes (1) . The activation domain of Tat (amino acids 1 to 48) interacts with the host Cdk9/cyclin T1, whereas the positively charged RNA-binding domain of Tat (amino acids 49-57) binds to the HIV-1 transactivation response (TAR) RNA (1) . Cdk9/cyclin T1 is a protein kinase that enhances transcriptional elongation by phosphorylating the C-terminal domain (CTD) of the largest subunit of RNA Polymerase II (RNAPII) (2) . The interaction of HIV-1 Tat with the bulge of TAR RNA and with cyclin T1 promotes binding of cyclin T1 to t he loop of TAR RNA (3) . As a result, Cdk9/cyclin T1 is recruited to the HIV-1 promoter (3, 4) . Cdk9-mediated phosphorylation of RNAPII CTD directly stimulates transcription elongation (5) . Cdk9 also stimulates elongation of transcription indirectly by relieving inhibition of transcription by several negative regulators, including the DRB sensitivity-inducing factor DSIF and the negative elongation factor NELF (6, 7) .
We recently demonstrated that protein phosphatase-1 (PP1) serves as a CTD phosphatase (8) . PP1 belongs to the PPP family of serine-threonine protein phosphatases, which also comprises PP2A (including PP4 and PP6), PP2B and PP5 (9) . PP1 holoenzymes consist of a constant catalytic subunit and one or two variable regulatory subunits (R) that determine the
Experimental Procedures
Materials-COS-7 cells, HEK 293, 84-31 and HeLa cells were purchased from ATCC (Manassas, VA). HeLa cells containing integrated HIV-1 LTR Lac Z and also expressing CD4 and T-tropic HIV-1 strain NL4-3 were obtained from AIDS Reagent Program (NIH). Anti-EGFP antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).
Preparation of recombinant proteins -HIV-1 Tat was expressed in Escherichia coli and purified on an Aquapore RP-300 column (Applied Biosystems, Foster City, CA) by reversedphase chromatography (15) . V201A/F203A (RATA mutant) were described (18) . The expression vector for PP1γ-EGFP was prepared as described (19) .
Plasmids -
β-galactosidase activity. Where indicated, Tat transactivation was induced 24 hours post transfection with JK2 by the addition of purified Tat (residues 1-72; 200 ng/ml) and 100 µM chloroquine, as previously described (20) . HeLa cells were cultured in DMEM containing 10% fetal bovine serum. Cells were grown to 75% confluency and transfected with Lipofectamine Plus (Life Technologies, Rockville, MD) according to the recommendations of the manufacturer. Cells were lysed 48 hours post transfection and analyzed for β-galactosidase activity and by FACS.
Recombinant adeno-associated viruses -Recombinant AAV vectors containing either the EGFP-fused NIPP1 gene under the control of the CMV promoter (AAV.NIPP1) or mutant EGFP-fused NIPP1 K193-197A/V201A/F203A/Y335D (AAV.pA-RATA Y335D) were produced as described (21) . Briefly, the cis plasmid (which contains the gene of interest with AAV ITRs), the trans plasmid (with the AAV rep and cap gene), and a helper plasmid (pF∆6, which contains an essential region from the Ad genome) were co-transfected into HEP-293 cells at a ratio of 1:1:2 by calcium phosphate precipitation in an Ad-free system. The cells were harvested 96h later. The AAV was purified through two rounds of CsCl density gradient centrifugation, desalted by dialysis at 4 0 C against PBS, aliquoted, and kept at 4°C. The titer was determined by quantitative dot blot hybridization. The purity of the AAV vector preparation was addressed by colloidal brilliant blue G staining (Sigma, St. Louis, MO) and Western blotting of viral proteins separated by SDS-PAGE.
Preparation of Adeno-Tat -The E1-deleted recombinant Ad carrying Tat was generated as previously described (22) . Briefly, a cDNA fragment encoding the full length HIV-1 Tat protein cloned into the plasmid pCXN was subcloned in the pAd.CMVlink plasmid. pAd.CMVlink and Cla I digested adenoviral DNA were co-transfected into HEP-293 cells at a ratio of 3:1 by calcium phosphate precipitation to allow the recombination. The virus was purified through three rounds of plaque-purification. Viruses were replicated in HEK-293 cells and were purified from a cell lysate by two rounds of CsCl density gradient centrifugation. The purified virus was desalted on a Bio-Gel P-6 desalting column (Bio-Rad Laboratories, Hercules, CA) equilibrated with PBS. The titer of the virus preparation was determined both by absorbency at 260 nm and by plaque assay (23). The particle to plaque forming unit ratio was less than 100. Purified viruses were suspended in PBS at the desired concentrations. 
Results

Expression of NIPP1-EGFP blocks HIV-1 activated transcription in cultured cells
-To analyze the contribution of PP1 to the control of HIV-1 transcription in intact cells, nuclear inhibitor of PP1 (NIPP1) was expressed as a fusion with the enhanced-green-fluorescentprotein (EGFP) in HEK 293, COS-7 or HeLa cells. It has been previously shown that the NIPP1-EGFP fusion protein was expressed to significantly higher levels than NIPP1 without this tag (18) . As a control, we used a mutated version of NIPP1-EGFP (NIPP1-(1-351)
K193-197A/V201A/F203A/Y335D, PI-mutant) that no longer interacts with PP1 (24) . In this mutant the PP1 binding sites in both the central and C-terminal domains of NIPP1 are mutated (24) . To explore whether the effects of NIPP1 were mediated by its intrinsic endoribonuclease activity, we also used a C-terminally truncated version NIPP1-(1-329), which lacks the RNA- induced HIV-1 transcription, we expressed a PP1 isoform, PP1γ -EGFP ( Fig.2A, lanes 3) .
Expression of PP1 per se did not affect the Tat-dependent transcription (Fig. 2C, lane 3) . But the NIPP1-EGFP mediated inhibition of Tat-dependent transcription (Fig. 2C , lane 4) was completely reversed by the expression of PP1 (Fig 2C, lane 5) . Our results indicate that NIPP1
inhibits Tat-dependent HIV-transcription because it inhibits PP1, which a ppears to be necessary for transcription. Overexpression of PP1 titrates NIPP1, which explains why coexpression of NIPP1 and PP1 is not inhibitory. The expression of Tat was analyzed in COS-7 cells transfected with the Tat-expressing vector and immunostained with anti-Tat polyclonal antibodies (Fig. 3) . Tat expression was visualized by indirect immunostaining with TRITC-labeled goat-anti-mouse antibodies (Fig. 3D) .
The inhibition of Tat-dependent transcription by NIPP1 is not the result of a reduced expression of Tat
No staining was found in untransfected cells (Fig. 3E) . We observed no significant difference in Tat expression in the cells transfected with Tat alone or co-transfected with Tat and either NIPP1-EGFP or mutant NIPP1-EGFP expression vectors (Figs. 3A and D) . Expression of NIPP1, analyzed earlier in Western blot (Fig. 1A) was monitored here by fluorescence of EGFP (Fig. 3B ).
To further investigate whether the inhibitory effect of NIPP1 on Tat-dependent transcription was dependent on the expression of Tat, HIV-1 transcription was activated by addition of purified Tat protein to the culture medium (20) . The purified Tat increased HIV-1 transcription about 5-fold (Fig. 4, lanes 1 and 2) . In contrast, HIV-1 LTR∆TAR, in which the TAR sequence was deleted, was only slightly (less than 2-fold) induced by Tat protein (Fig. 4 , lanes 5 and 6). Again, the expression of NIPP1-EGFP but not the mutant NIPP1-EGFP blocked the Tat-induced transcription (Fig. 4, lanes 3 and 4) . In contrast, neither NIPP1-EGFP nor mutant NIPP1-EGFP expression has an effect on transcription from the mutant HIV-1 LTR∆TAR (Fig. 4, lanes 5, 6 and 7) . Taken together, our results indicate that the expression of NIPP1-EGFP blocked Tat-activated transcription and that this effect was not the result of a decreased expression of Tat. (Fig. 5A, lanes 3 and 4). Because both NIPP1 and the PI-mutant of NIPP1 were expressed as fusions with EGFP, allowing equal infectivity to be ensured, their distinct effects cannot be ascribed to differences in gene delivery efficiency (Fig. 5B) . These results indicate that PP1 is an essential factor also during HIV-1 transcription from the integrated HIV-1 promoter. (Fig.6A, lane 4, and Fig.6E ). In non-infected cells, the expression of HIV-1 LTR was not detectable (Fig.6 F) . These results indicate that inhibition of PP1 efficiently blocks HIV-1 viral replication.
Adeno-associated virus (AAV) -mediated delivery of NIPP1 inhibits induced HIV-
AAV -mediated delivery of NIPP1 inhibits replication of HIV-1 -
Discussion
Recent studies firmly established that Tat-induced transcription from the HIV-1 promoter is regulated at the level of RNAPII CTD phosphorylation (1, 2) . While the role of the Tatassociated CTD kinase Cdk9/cyclin T1 has been well established (2), the role of the protein phosphatases in the function of Tat is not very well understood. RNAP II CTD is dephosphorylated by a well-established CTD phosphatase, FCP1 (26) . Tat inhibits FCP1, and this inhibition may alleviate FCP1-mediated pausing of transcription (12, 13) . We have recently reported that PP1 also functions as a CTD phosphatase (8) . We have shown that PP1 and FCP1 contribute equally to the dephosphorylation of RNAPII in vitro (8) . In vivo a PPP-type phosphatase dephosphorylates approximately 40% of all RNAPII when cells are treated with high concentrations of flavopiridol (8) . Interestingly, PP1 associates with the preinitiation complex and stimulates transcription from the HIV-1 promoter in vitro (14) . Therefore we asked whether the inhibition of PP1 by overexpression of NIPP1, a nuclear inhibitor of PP1 (9), might have a regulatory effect in HIV-1 transcription. NIPP1 inhibits the dephosphorylation of a variety of substrates by PP1 including phosphorylase a (10). Reported NIPP1-mediated inhibition of splicing in vitro is independent of its ability to inhibit PP1 (27, 28) . Recent studies showed that the expression of NIPP1 in Drosophila is lethal and that this phenotype is reversed by co-expression of PP1, indicating that the lethality stems from the inhibition of PP1 (29) . It is unclear which nuclear process is affected and causes the embryonic lethality of the NIPP1 transgenic flies, but our studies ( [14] and the present study) show that PP1 has an effect on transcription. Indeed, in the present paper we provide evidence that overexpression of NIPP1 inhibits HIV-1 transcription and that the inhibition correlates with the ability of NIPP1 to bind and inhibit PP1.
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